Email updates

Keep up to date with the latest news and content from Breast Cancer Research and BioMed Central.

This article is part of the supplement: Breast Cancer Research 2008

Poster presentation

Bevacizumab resistance in breast cancer: are neuropilins the key?

CA Staton, Z Yang, MWR Reed and NJ Brown

Author Affiliations

Microcirculation Research Group, Academic Surgical Oncology Unit, Section of Oncology, School of Medicine and Biomedical Sciences, University of Sheffield, UK

For all author emails, please log on.

Breast Cancer Research 2008, 10(Suppl 2):P75  doi:10.1186/bcr1959

The electronic version of this article is the complete one and can be found online at: http://breast-cancer-research.com/content/10/S2/P75


Published:13 May 2008

© 2008 BioMed Central Ltd

Background

During breast cancer growth and development, angiogenesis is triggered by the interaction between vascular endothelial growth factor (VEGF) and its receptors VEGF-R1 and VEGF-R2. In breast cancer, alternative VEGF receptors, the neuropilins (Np1 and Np2), are often upregulated and serve to augment the effects of VEGF-R1/VEGF-R2 binding and provide alternative signalling pathways. Recently, a humanized antibody, Bevacizumab (Bz), which prevents VEGF binding to VEGF-R1/VEGF-R2, in combination with chemotherapy demonstrated initial efficacy (increased progression-free survival) in breast cancer phase III clinical trials. Eventually, however, the tumours evade treatment control. This may be because neuropilins are not blocked by Bz and provide an alternative VEGF signalling pathway in breast cancer. Therefore the present study aims to evaluate the potential of enhancing efficacy of Bz treatment by simultaneously blocking VEGF–neuropilin binding.

Methods

Western blot analysis of VEGF receptors in human endothelial cells (HUVEC and HuDMEC) and breast cancer cell lines (MDA-MB-436, MCF-7 and T47D) assessed relative expressions of VEGF-R1, VEGF-R2, Np1 and Np2 in these cells. Microvascular endothelial tubule formation assays were then performed in vitro where cells were incubated on Matrigel in the presence of VEGF for 24 hours, and then Bz (1 to 4 mg/ml) and/or anti-Np (50 to 100 ng/ml) antibody were added to the wells. The number of branch points were quantified in three fields of view/well in three separate experiments.

Results

Western blot analysis revealed Np1 and Np2 expression in both breast cancer and endothelial cell lines, whereas VEGF-R1 is expressed in MCF-7, MDA-MB-436 and endothelial cells and VEGF-R2 is only expressed by endothelial cells. HuDMEC stimulated by VEGF formed tubules in vitro, and the number of branch points/field of view for VEGF-stimulated controls (43 ± 6) versus Bz (25 ± 3) versus anti-NP antibody (26 ± 4) versus Bz + anti-Np antibody (17 ± 3) demonstrated a significant (P < 0.001) reduction in tubule formation.

Conclusion

These data show that anti-Np antibodies increase the inhibitory effect of Bz and suggest that efficacy of breast cancer treatment with Bz may be enhanced by addition of a neuropilin blocking agent.